Medicine and Dentistry
Radionuclide Therapy
100%
Peptide Receptor
92%
Neuroendocrine Tumor
84%
Lutetium 177
54%
Prostate Specific Membrane Antigen
38%
Prostate Cancer
34%
Positron Emission Tomography
31%
Gallium 68
28%
Positron Emission Tomography-Computed Tomography
26%
Neoplasm
24%
Tetraxetan
22%
Progression Free Survival
19%
Overall Survival
15%
Somatostatin Derivative
14%
Liver Metastasis
14%
Castration Resistant Prostate Cancer
13%
Diseases
13%
Radiomics
13%
Prostatectomy
13%
Actinium 225
13%
Gastroenteropancreatic Neuroendocrine Tumor
9%
Computer Assisted Tomography
8%
Biochemical Recurrence
8%
Bone Marrow Toxicity
7%
Carcinoid Syndrome
7%
Prostate Specific Antigen
7%
Tumor Progression
7%
Fluorine-18
7%
Radioisotope
6%
Metastatic Carcinoma
6%
Systematic Review
6%
Meta-Analysis
6%
Adenoma
6%
Middle Ear
6%
Cancer Recurrence
6%
Deoxyglucose
6%
Glucose Uptake
6%
Meningioma
6%
False Positive Result
6%
Blood Toxicity
6%
DOPA
6%
PET-MRI
6%
Radioembolization
6%
Hyperammonemia
6%
Adenocarcinoma
6%
Long Term Survival
6%
Talimogene Laherparepvec
6%
Salivary Gland
6%
Radiation Therapy
6%
Gland Tissue
6%
Pharmacology, Toxicology and Pharmaceutical Science
Radioisotope
75%
Lutetium 177
57%
Receptor
56%
Actinium 225
39%
Neuroendocrine Tumor
36%
Tetraxetan
22%
Prostate Specific Membrane Antigen
19%
Castration Resistant Prostate Cancer
17%
Progression Free Survival
14%
Gastroenteropancreatic Neuroendocrine Tumor
14%
Prostate Cancer
13%
Overall Survival
9%
Chemotherapy
8%
Bone Marrow Toxicity
7%
Diseases
7%
Neoplasm
7%
Malignant Neoplasm
7%
Good Manufacturing Practice
7%
Meningioma
6%
Fluorodeoxyglucose F 18
6%
Sunitinib
6%
Everolimus
6%
Tolerability
6%
Carcinoid Syndrome
6%
Long Term Survival
6%
Cancer Recurrence
6%
Biochemical Recurrence
6%
Cardiac Sarcoidosis
6%
Tumor Growth
6%
High Performance Liquid Chromatography
5%
Prostate Specific Antigen
5%